POG Pharmacometrics is a small pharmacometric consultancy company We aim to help you use the data that has been collected during drug-development in an integrated way, across studies, as a quantitative basis for making decisions. We can also include available information from other compounds in the disease area. By combining the data with available knowledge of physiology, pharmacology and drug properties, we can make models. These models can be used to simulate various what-if scenarios. The outcomes of these simulations can be used to answer questions and to support decision making during drug development. We have experience of answering a wide range of questions, in all phases of drug development, using data on endpoints, surrogate endpoints, biomarkers and pharmacokinetics. For example: What is the dose and regimen to take forward to the next development stage? Is this compound likely to be better than current Standard of Care? How is this drug different from it's competitors? What is the likelihood of meeting the suggested target profile? How do we extrapolate the results from a short Proof of Concept study to long term treatment? Is there a sub-population of patients that is likely to respond better to treatment? Should the dose be individualised? What is the consequence of using different dose adjustment schedules? What is the best practical design for our next study? We offer the following Services: Population pharmacokinetic modelling Modelling and prediction of pharmacokinetics in special populations, including children Target mediated drug disposition Pharmacokinetic / Pharmacodynamic modelling Semi-mechanistic and mechanistic pharmacodynamic models Exposure/Response modelling Endpoint modelling: time to event/survival models, logistic models, categorical endpoint models, etc. Adverse event modelling Clinical trial simulations Study design and dose selection for studies from first in man to phase three. We offer the following Services: Population pharmacokinetic modelling Modelling and prediction of pharmacokinetics in special populations, including children Target mediated drug disposition Pharmacokinetic / Pharmacodynamic modelling Semi-mechanistic and mechanistic pharmacodynamic models Exposure/Response modelling Endpoint modelling: time to event/survival models, logistic models, categorical endpoint models, etc. Adverse event modelling Clinical trial simulations Study design and dose selection for studies from first in man to phase three. Animal Rule studies We also offer Training and Mentoring in the above areas.